Akebia (AKBA) Therapeutics announced that in late November U.S. Renal Care enrolled the first patient in its Vafseo Outcomes In-Center Experience collaborative trial. Akebia announced the collaborative trial initiation in September 2024. The VOICE trial intends to enroll approximately 2,200 patients who will be randomized to oral Vafseo 300 mg tablets administered three times per week or standard-of-care erythropoiesis-stimulating agents. The trial will end approximately 18 months after the last patient is randomized. The primary endpoint is non-inferiority for all-cause mortality and the secondary endpoint will test superiority of Vafseo to reduce all-cause hospitalization.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AKBA:
- Biotech Alert: Searches spiking for these stocks today
- Akebia Therapeutics Prepares for Vafseo Launch
- Akebia reports Q3 EPS (10c), consensus (6c)
- AKBA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- GE Aerospace, GM report quarterly earnings beats: Morning Buzz
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
